<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01711879</url>
  </required_header>
  <id_info>
    <org_study_id>12-1526</org_study_id>
    <nct_id>NCT01711879</nct_id>
  </id_info>
  <brief_title>Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma</brief_title>
  <official_title>Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 52 week study will assess the use of intravitreal aflibercept injections in patients&#xD;
      with neovascular glaucoma (NVG) compared to standard of care panretinal photocoagulation.&#xD;
&#xD;
      The investigators hypothesize that the neovascularization of the iris and angle present in&#xD;
      neovascular glaucoma will resolve more quickly in eye treated with intravitreal aflibercept&#xD;
      injection alone and result in increased comfort and preservation of visual field as compared&#xD;
      to current standard of care utilizing pan-retinal photocoagulation. The advantages to&#xD;
      intravitreal aflibercept injection use could include resolution of NVI/NVA&#xD;
      (neovascularization of the iris/neovascularization of the angle) leading to quicker pain&#xD;
      relief and quicker lowering of IOP (intraocular pressure).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The two arms of this study will compare current common practice (initial intravitreal&#xD;
      anti-VEGF (vascular endothelial growth factor) to study treatment (VEGF) injection only) for&#xD;
      52 weeks.&#xD;
&#xD;
      This single center study will consist of 20 patients with NVG. Patients will be randomized&#xD;
      to:&#xD;
&#xD;
        -  Group A: A single injection of 2mg (0.05ml) intravitreal aflibercept injection at&#xD;
           baseline followed by standard of care laser with observation for a total of 52 weeks.&#xD;
&#xD;
      or&#xD;
&#xD;
        -  Group B: 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two&#xD;
           additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52&#xD;
           weeks.&#xD;
&#xD;
      Clinical assessment will include pain assessment (Universal Pain Scale), best corrected&#xD;
      visual acuity (ETDRS), ophthalmic examination, anterior segment assessment including number&#xD;
      of clock-hours of NVI/NVA, gonioscopy, anterior segment photography, visual field test&#xD;
      (Humphrey SITA- Standard 24-2), optic nerve OCT (Zeiss Cirrus Optic Disc Cube 200x200),&#xD;
      macular OCT (Cube scan 512 x 128 and 5 Line Raster), fluorescein angiography (initial iris&#xD;
      phase followed by standard retinal angiography), and concurrent medical/ocular medications.&#xD;
      Qualitative assessment of neovascularization will be made by the investigator based on&#xD;
      comparison to baseline angiography.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>2 year</time_frame>
    <description>Assess the safety profile of repeated intravitreal aflibercept injections in patients with NVG by evaluating the incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Adverse Events</measure>
    <time_frame>2 year</time_frame>
    <description>Assess the safety profile of repeated intravitreal aflibercept injections in patients with NVG by evaluating the severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Resolution of Neovascularization</measure>
    <time_frame>1 year</time_frame>
    <description>Compare between Groups A and B the Rate and extent of resolution of neovascularization in patients with NVG Stages 1 &amp; 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure (mmHg) at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Intraocular pressure(mmHg) as measured by Goldmann applanation tonometry between groups A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure (mmHg) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Mean intraocular pressure(mmHg) as measured by Goldmann applanation tonometry between groups A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Losing &gt; 5 Letters on Visual Acuity in Each Group A and Group B</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Comparison between patients, groups A and B, that lost &gt; 5 letters on visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Each, Group A and Group B, Gaining &gt; 5 Letters on Visual Acuity</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Comparison of patients in each, group A and group B, that gained &gt; 5 letters on visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Comparison of visual acuity between groups A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Comparison of visual acuity at Week 52 between groups A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Visual Field Between Groups</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the Visual field s measured by HVF 24-2 SITA Standards between groups A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of the Optical Coherence Tomography(OCT) Outcomes</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Evaluation of the Optical Coherence Tomography(OCT) outcomes (average retinal nerve fiber layer(RNFL) and central macular thickness), Compared between groups A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Need for Surgical Intervention</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison between groups A and B and the need for surgical intervention in both arms during the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Need for Additional IOP Lowering Medications</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison between groups A and B for the need of additional IOP lowering medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of Resolution of Neovascularization Between Groups</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of groups A and B and the extent of resolution of neovascularization in patients with NVG Stages 1 &amp; 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Average Retinal Nerve Fiber Layer (RNFL)</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison between groups A and B of the average retinal nerve fiber layer (RNFL) as measured by Optical Coherence Tomography (OCT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Neovascular Glaucoma</condition>
  <arm_group>
    <arm_group_label>Aflibercept with Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Details covered in arm description</description>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_label>Aflibercept with Laser</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of neovascular glaucoma (Stage I-II)&#xD;
&#xD;
          -  Individuals who are ages 21-90 years old; male or female of any race&#xD;
&#xD;
          -  Presence of neovascularization of the iris and/or angle&#xD;
&#xD;
          -  At least 90 degrees of &quot;unzipped&quot; anterior chamber angle as noted by gonioscopy. (a&#xD;
             &quot;zipped angle is the term used for a drainage angle that is slowly closing due to scar&#xD;
             tissue from the neovascularization process)&#xD;
&#xD;
          -  Visual acuity of light perception or better in the study eye&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study-related procedures&#xD;
&#xD;
          -  Provide signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of intravitreal anti-VEGF agents in the study eye in the past 3 months.&#xD;
&#xD;
          -  Full PRP in the study eye&#xD;
&#xD;
          -  Prior vitrectomy in the study eye&#xD;
&#xD;
          -  Prior trabeculectomy or other filtration surgery in the study eye&#xD;
&#xD;
          -  Active ocular or periocular infection in the study eye&#xD;
&#xD;
          -  Ocular conditions (Cataract or vitreous hemorrhage) that might require surgery in next&#xD;
             12 months&#xD;
&#xD;
          -  Allergy to fluorescein dye&#xD;
&#xD;
          -  Any past use of systemic anti-VEGF medication&#xD;
&#xD;
          -  Myocardial infarction within 6 months prior to study enrollment&#xD;
&#xD;
          -  Stroke within 6 months prior to study enrollment&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Sexually active men or women of childbearing potential who are unwilling to practice&#xD;
             adequate contraception during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malik Y Kahook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Lions Eye Institute</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 18, 2012</study_first_submitted>
  <study_first_submitted_qc>October 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2012</study_first_posted>
  <results_first_submitted>March 20, 2017</results_first_submitted>
  <results_first_submitted_qc>December 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Neovascular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aflibercept With Laser</title>
          <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>Aflibercept</title>
          <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aflibercept With Laser</title>
          <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks&#xD;
Aflibercept: Details covered in arm description</description>
        </group>
        <group group_id="B2">
          <title>Aflibercept</title>
          <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.&#xD;
Aflibercept: Details covered in arm description</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.33" spread="5.69"/>
                    <measurement group_id="B2" value="61.5" spread="15.63"/>
                    <measurement group_id="B3" value="59.29" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events</title>
        <description>Assess the safety profile of repeated intravitreal aflibercept injections in patients with NVG by evaluating the incidence of adverse events</description>
        <time_frame>2 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Assess the safety profile of repeated intravitreal aflibercept injections in patients with NVG by evaluating the incidence of adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severity of Adverse Events</title>
        <description>Assess the safety profile of repeated intravitreal aflibercept injections in patients with NVG by evaluating the severity of adverse events</description>
        <time_frame>2 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Adverse Events</title>
          <description>Assess the safety profile of repeated intravitreal aflibercept injections in patients with NVG by evaluating the severity of adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abcess left thigh</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitreous hemorrhage</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening cataract non-study eye</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening Cataract Study eye</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes Mellitus</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening NVG - non-study eye</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrent BCC</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>progression of gall bladder cancer</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>worsening of arthritis Right knee</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>matastatic cancer of liver</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>shortness of breath</title>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Resolution of Neovascularization</title>
        <description>Compare between Groups A and B the Rate and extent of resolution of neovascularization in patients with NVG Stages 1 &amp; 2.</description>
        <time_frame>1 year</time_frame>
        <population>No data was collected or analyzed for this Outcome Measure</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Resolution of Neovascularization</title>
          <description>Compare between Groups A and B the Rate and extent of resolution of neovascularization in patients with NVG Stages 1 &amp; 2.</description>
          <population>No data was collected or analyzed for this Outcome Measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraocular Pressure (mmHg) at Baseline</title>
        <description>Intraocular pressure(mmHg) as measured by Goldmann applanation tonometry between groups A and B</description>
        <time_frame>Baseline</time_frame>
        <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (mmHg) at Baseline</title>
          <description>Intraocular pressure(mmHg) as measured by Goldmann applanation tonometry between groups A and B</description>
          <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Eye Mean IOP(mmHg) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="08" upper_limit="12"/>
                    <measurement group_id="O2" value="23.5" lower_limit="14" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow Eye Mean IOP(mmHg) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="08" upper_limit="14"/>
                    <measurement group_id="O2" value="22.75" lower_limit="17" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraocular Pressure (mmHg) at Week 52</title>
        <description>Mean intraocular pressure(mmHg) as measured by Goldmann applanation tonometry between groups A and B</description>
        <time_frame>Week 52</time_frame>
        <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (mmHg) at Week 52</title>
          <description>Mean intraocular pressure(mmHg) as measured by Goldmann applanation tonometry between groups A and B</description>
          <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Eye Mean IOP(mmHg) at W52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="08" upper_limit="12"/>
                    <measurement group_id="O2" value="15.25" lower_limit="13" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow Eye Mean IOP(mmHg) at W52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="08" upper_limit="12"/>
                    <measurement group_id="O2" value="14" lower_limit="06" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Losing &gt; 5 Letters on Visual Acuity in Each Group A and Group B</title>
        <description>Comparison between patients, groups A and B, that lost &gt; 5 letters on visual acuity</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Losing &gt; 5 Letters on Visual Acuity in Each Group A and Group B</title>
          <description>Comparison between patients, groups A and B, that lost &gt; 5 letters on visual acuity</description>
          <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Each, Group A and Group B, Gaining &gt; 5 Letters on Visual Acuity</title>
        <description>Comparison of patients in each, group A and group B, that gained &gt; 5 letters on visual acuity</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Each, Group A and Group B, Gaining &gt; 5 Letters on Visual Acuity</title>
          <description>Comparison of patients in each, group A and group B, that gained &gt; 5 letters on visual acuity</description>
          <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity at Baseline</title>
        <description>Comparison of visual acuity between groups A and B</description>
        <time_frame>Baseline</time_frame>
        <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity at Baseline</title>
          <description>Comparison of visual acuity between groups A and B</description>
          <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Eye Mean Baseline Number of ETDRS Letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="34" upper_limit="34"/>
                    <measurement group_id="O2" value="37.5" lower_limit="0" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow Eye Mean Baseline Number of ETDRS Letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="38.75" lower_limit="0" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity at Week 52</title>
        <description>Comparison of visual acuity at Week 52 between groups A and B</description>
        <time_frame>Week 52</time_frame>
        <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity at Week 52</title>
          <description>Comparison of visual acuity at Week 52 between groups A and B</description>
          <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Eye Mean W52 Number of ETDRS Letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" lower_limit="0" upper_limit="67"/>
                    <measurement group_id="O2" value="62" lower_limit="34" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow Eye Mean W52 Number of ETDRS Letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="0" upper_limit="64"/>
                    <measurement group_id="O2" value="46.75" lower_limit="0" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of the Visual Field Between Groups</title>
        <description>Comparison of the Visual field s measured by HVF 24-2 SITA Standards between groups A and B</description>
        <time_frame>1 year</time_frame>
        <population>No data was collected or analyzed for this Outcome Measure during the clinical trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Visual Field Between Groups</title>
          <description>Comparison of the Visual field s measured by HVF 24-2 SITA Standards between groups A and B</description>
          <population>No data was collected or analyzed for this Outcome Measure during the clinical trial.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure of the Optical Coherence Tomography(OCT) Outcomes</title>
        <description>Evaluation of the Optical Coherence Tomography(OCT) outcomes (average retinal nerve fiber layer(RNFL) and central macular thickness), Compared between groups A and B.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The database in OCT was corrupted and the data was lost</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks&#xD;
Aflibercept: Details covered in arm description</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.&#xD;
Aflibercept: Details covered in arm description</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of the Optical Coherence Tomography(OCT) Outcomes</title>
          <description>Evaluation of the Optical Coherence Tomography(OCT) outcomes (average retinal nerve fiber layer(RNFL) and central macular thickness), Compared between groups A and B.</description>
          <population>The database in OCT was corrupted and the data was lost</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Need for Surgical Intervention</title>
        <description>Comparison between groups A and B and the need for surgical intervention in both arms during the follow-up period</description>
        <time_frame>1 year</time_frame>
        <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Need for Surgical Intervention</title>
          <description>Comparison between groups A and B and the need for surgical intervention in both arms during the follow-up period</description>
          <population>One participant from group Aflibercept with Laser did not complete analysis due to death. Analysis is limited due to small sample size.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Need for Additional IOP Lowering Medications</title>
        <description>Comparison between groups A and B for the need of additional IOP lowering medications</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Need for Additional IOP Lowering Medications</title>
          <description>Comparison between groups A and B for the need of additional IOP lowering medications</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extent of Resolution of Neovascularization Between Groups</title>
        <description>Comparison of groups A and B and the extent of resolution of neovascularization in patients with NVG Stages 1 &amp; 2</description>
        <time_frame>1 year</time_frame>
        <population>NVG Staging not recorded</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Extent of Resolution of Neovascularization Between Groups</title>
          <description>Comparison of groups A and B and the extent of resolution of neovascularization in patients with NVG Stages 1 &amp; 2</description>
          <population>NVG Staging not recorded</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Average Retinal Nerve Fiber Layer (RNFL)</title>
        <description>Comparison between groups A and B of the average retinal nerve fiber layer (RNFL) as measured by Optical Coherence Tomography (OCT)</description>
        <time_frame>1 year</time_frame>
        <population>The OCT database was corrupted and the data was lost</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept With Laser</title>
            <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept</title>
            <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Average Retinal Nerve Fiber Layer (RNFL)</title>
          <description>Comparison between groups A and B of the average retinal nerve fiber layer (RNFL) as measured by Optical Coherence Tomography (OCT)</description>
          <population>The OCT database was corrupted and the data was lost</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aflibercept With Laser</title>
          <description>A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>Aflibercept</title>
          <description>2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous hemmorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Worsening cataract non-study eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Worsening Cataract Study eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Worsening NVG - non-study eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>progression of gall bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>metastatic cancer affecting liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>worsening arthritis right knee</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Recurrent BCC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abcess left thigh</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rachel Gerle</name_or_title>
      <organization>University of Colorado School of Medicine</organization>
      <phone>720-848-2020</phone>
      <email>rachel.gerle@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

